1KinBio

1Kin Bio is a preclinical-stage biotechnology company dedicated to developing selective kinase inhibitors for respiratory and fibrotic diseases. The company's primary focus is on the Rho-associated coiled-coil containing protein kinase (ROCK) pathway, which plays a critical role in tissue remodeling and inflammation. Their lead candidate, 1KIN-001, is being developed as a potentially best-in-class treatment for idiopathic pulmonary fibrosis (IPF). By optimizing the selectivity and pharmacokinetic profiles of their compounds, 1Kin Bio seeks to minimize systemic side effects associated with earlier generations of ROCK inhibitors. The company was founded by industry veterans and is supported by leading venture capital firms.